|
KMID : 0311120190600030277
|
|
Yonsei Medical Journal
2019 Volume.60 No. 3 p.277 ~ p.284
|
|
|
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
|
|
Lee So-Ryoung
Lee Young-Soo
Park Ji-Suck
Cha Myung-Jin
Kim Tae-Hoon
Park Jun-Beom
Park Jin-Kyu
Lee Jung-Myung
Kang Ki-Woon
Shim Jae-Min
Uhm Jae-Sun
Kim Jun
Kim Chang-Soo
Kim Jin-Bae
Park Hyung-Wook
Joung Bo-Young
Choi Eue-Keun
|
|
|
Abstract
|
|
|
Purpose: Label adherence for non-vitamin K antagonist oral anticoagulants (NOACs) has not been well evaluated in Asian patients with non-valvular atrial fibrillation (AF). The present study aimed to assess label adherence for NOACs in a Korean AF population and to determine risk factors of off-label prescriptions of NOACs.
Materials and Methods: In this COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, patients with AF who were prescribed NOACs between June 2016 and May 2017 were included. Four NOAC doses were categorized as on- or off-label use according to Korea Food and Drug Regulations.
Results: We evaluated 3080 AF patients treated with NOACs (dabigatran 27.2%, rivaroxaban 23.9%, apixaban 36.9%, and edoxaban 12.0%). The mean age was 70.5±9.2 years; 56.0% were men; and the mean CHA2DS2-VASc score was 3.3±1.4. Only one-third of the patients (32.7%) was prescribed a standard dose of NOAC. More than one-third of the study population (n=1122, 36.4%) was prescribed an off-label reduced dose of NOAC. Compared to those with an on-label standard dosing, patients with an off-label reduced dose of NOAC were older (≥75 years), women, and had a lower body weight (≤60 kg), renal dysfunction (creatinine clearance ≤50 mL/min), previous stroke, previous bleeding, hypertension, concomitant dronedarone use, and anti-platelet use.
Conclusion: In real-world practice, more than one-third of patients with NOAC prescriptions received an off-label reduced dose, which could result in an increased risk of stroke. Considering the high risk of stroke in these patients, on-label use of NOAC is recommended.
|
|
|
KEYWORD
|
|
|
Atrial fibrillation, non-vitamin K antagonist oral anticoagulant, drug labeling, dose
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|